NCT03310619 - A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions

Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular

Interventions

BIOLOGICAL

JCAR017

Gene modified autologous T cells

DRUG

Durvalumab

Anti-PD-L1

DRUG

CC-122

Pleiotropic Pathway Modifier

DRUG

Ibrutinib

DRUG

CC-220

DRUG

Relatlimab

DRUG

Nivolumab

DRUG

CC-99282

Trial Locations (9)

15232

Local Institution - 020, Pittsburgh

19104

Local Institution - 016, Philadelphia

30342

Local Institution - 022, Atlanta

77030

Local Institution - 013, Houston

91010

Local Institution - 011, Duarte

60611-5975

Local Institution - 014, Chicago

02114

Local Institution - 012, Boston

02215

Local Institution - 021, Boston

68198-7680

Local Institution - 015, Omaha